OPKO Health, Inc. Interest Expense
OPKO Health, Inc. (OPK) reported Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-02-26
- OPKO Health, Inc. interest expense for the quarter ending 2024-03-31 was $7.69M, a 126.66% increase year-over-year.
- OPKO Health, Inc. interest expense for the quarter ending 2023-12-31 was $3.45M, a 4.57% increase year-over-year.
- OPKO Health, Inc. interest expense for the quarter ending 2023-09-30 was $3.38M, a 12.16% increase year-over-year.
- OPKO Health, Inc. interest expense for the quarter ending 2023-06-30 was $3.28M, a 6.57% increase year-over-year.
- OPKO Health, Inc. interest expense for fiscal 2025 was $0.00.
- OPKO Health, Inc. interest expense for fiscal 2023 was $13.51M, a 12.03% increase from fiscal 2022.
- OPKO Health, Inc. interest expense for fiscal 2022 was $12.06M, a 36.14% decline from fiscal 2021.
- OPKO Health, Inc. interest expense for fiscal 2021 was $18.88M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-03-31 | $7.69M 10-Q · filed 2024-05-07 | $11.14M derived: sum of 2 quarters · filed 2024-05-07 | $14.52M derived: sum of 3 quarters · filed 2024-05-07 | $17.80M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $6.84M derived: sum of 2 quarters · filed 2024-03-01 | $10.11M derived: sum of 3 quarters · filed 2024-03-01 | $13.51M 10-K · filed 2024-03-01 |
| 2023-09-30 | $3.38M 10-Q · filed 2023-11-06 | $6.66M derived: sum of 2 quarters · filed 2023-11-06 | $10.05M 10-Q · filed 2023-11-06 | $13.35M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $3.28M 10-Q · filed 2023-08-03 | $6.67M 10-Q · filed 2023-08-03 | $9.97M derived: sum of 3 quarters · filed 2024-05-07 | $12.99M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $3.39M 10-Q · filed 2024-05-07 | $6.69M derived: sum of 2 quarters · filed 2024-05-07 | $9.71M derived: sum of 3 quarters · filed 2024-05-07 | $12.79M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $6.32M derived: sum of 2 quarters · filed 2024-03-01 | $9.39M derived: sum of 3 quarters · filed 2024-03-01 | $12.06M 10-K · filed 2024-03-01 |
| 2022-09-30 | $3.02M 10-Q · filed 2023-11-06 | $6.09M derived: sum of 2 quarters · filed 2023-11-06 | $8.75M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $3.08M 10-Q · filed 2023-08-03 | $5.74M 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $18.88M 10-K · filed 2024-03-01 | |||
| 2012-03-31 | $351.00K 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | $1.00M 10-K · filed 2012-03-15 | |||
| 2011-03-31 | $87.00K 10-Q · filed 2012-05-10 | |||
| 2010-12-31 | $1.22M 10-K · filed 2012-03-15 | |||
| 2009-12-31 | $1.76M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |